Wenyu Huang
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1194989491
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $220,429 of the $340,999 with a category attached, or 64.6%. 15 manufacturers reported payments, led by Recordati_rare_diseases_inc. at 31.7% of the total. 2025 is the largest year on record at $141,990, more than ten times the $5,734 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $1055.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Recordati_rare_diseases_inc.$108K
- Neurocrine Biosciences, Inc.$70K
- Amryt Pharma Holdings Ltd$64K
- Chiesi USA, Inc.$45K
- Chiasma, Inc.$25K
- Novo Nordisk$12K
- plus $16K from 9 others
Across 107 payments — averaging $2840.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$101K
- Ascendis Pharma Endocrinology Inc$92K
- Corcept Therapeutics$56K
- Amryt Pharma Holdings Ltd$34K
- Chiasma, Inc.$13K
- Novartis$6K
- plus $410 from 1 others
What the payments were for
- Consulting fees$84,58625%
- Speaking & faculty fees$220,42965%
- Travel & lodging$29,5749%
- Food & beverage$6,1142%
- Education$2960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Recordati_rare_diseases_inc. | 68 | $107,947 |
| Neurocrine Biosciences, Inc. | 92 | $70,155 |
| Amryt Pharma Holdings Ltd | 61 | $63,681 |
| Chiesi USA, Inc. | 47 | $45,450 |
| Chiasma, Inc. | 17 | $25,422 |
| Novo Nordisk | 12 | $12,242 |
| Xeris Pharmaceuticals, Inc. | 4 | $7,392 |
| Corcept Therapeutics | 14 | $6,195 |
| Pfizer | 2 | $895 |
| Tolmar, Inc. | 1 | $535 |
| Sanofi-aventis U.S. LLC | 1 | $400 |
| Abbott | 1 | $375 |
| Sanofi | 1 | $185 |
| AstraZeneca | 1 | $108 |
| Esteve Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$133,316
- ISTURISA$84,783
- CRENESSITY$48,031
- SIGNIFOR LAR$11,104
- Sogroya$7,134
- RECORLEV$6,545
- Korlym$5,747
- Norditropin$2,250
- SOMAVERT$880
- SOLIQUA 100/33$400
- FreeStyle Libre Pro$375
- TOUJEO$185
- MYALEPT$104
- JUXTAPID$104
How this compares
$340,999 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 23 | $723,874 |
| Signifor LarPasireotide Pamoate | 30 | $570,004 |
| IsturisaOsilodrostat Phosphate | 13 | $417,746 |
| TrulicityDulaglutide | 181 | $301,828 |
| OzempicSemaglutide | 151 | $249,780 |
| JardianceEmpagliflozin | 120 | $192,170 |
| MycapssaOctreotide Acetate | 16 | $105,792 |
| MounjaroTirzepatide | 59 | $90,599 |
| OmnitropeSomatropin | 13 | $61,315 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $34,459 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $32,414 |
| InvokanaCanagliflozin | 18 | $30,186 |
| TradjentaLinagliptin | 18 | $25,380 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 42 | $25,241 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $24,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Recordati_rare_diseases_inc.Signifor Lar, Isturisa | $107,947 | $987,75043 claims |
| Corcept TherapeuticsKorlym | $6,195 | $723,87423 claims |
| Novo NordiskOzempic | $12,242 | $249,780151 claims |
| Chiesi USA, Inc.Mycapssa | $45,450 | $105,79216 claims |
| AstraZenecaFarxiga | $108 | $15,76821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
- Hong LeeChicago$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.